Sygnis Pulls in $24M in Rights Offering for Stroke Drug Trial Oct. 22, 2008 By Cormac Sheridan Underlining the value of having big backers in these straitened times, Sygnis Pharma AG unveiled an €18.3 million (US$24.4 million) rights offering that already is fully backed by its two largest shareholders. (BioWorld International)Read More
RSS